Upsher-Smith Completes Acquisition Of Dr Reddy’s Two Migraine Treatments
Executive Summary
Upsher-Smith strategically expands and diversifies its portfolio by acquiring Dr Reddy’s two treatments of acute migraine in adults.
You may also be interested in...
Sawai’s Upsher-Smith Gets New Leadership Amid ‘Drastic Restructuring’
A major overhaul is in progress for Sawai’s Upsher-Smith business, after the Japanese parent company announced leadership changes and a “drastic restructuring” of the US unit in the wake of a significant impairment charge and a hefty annual operating loss that dragged down Sawai’s overall results.
Sawai Sets Out US Recalibration
Sawai Pharmaceutical has major plans for its US business that include consolidating its manufacturing operations at a single site and bolstering its pipeline and portfolio, Sawai president Kenzo Sawai tells Generics Bulletin in an exclusive interview.
Upsher-Smith Launches Three New Generics
Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.